Products and Services

Text with Title

Evaluate gives you the understanding and time you need to drive better decisions

Evaluate's beginning focused on providing consensus forecasts that distilled the insight of pharmaceutical equity analysts around the world. These are still the foundation of our services. Get up-to-date, robust forecasts aggregating a wealth of equity analyst research into a single standardised source. Ensure your analysis reaches the crux of the matter. From an overview of the broader market to a detailed product or company analysis, Evaluate's integrated platform is designed to take you from exploration to full understanding as quickly and accurately as possible. 

Explore our forecasts

EvaluatePharma
OUR PRODUCTS
EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the first single view of the risk and reward of the R&D landscape from EvaluatePharma Vision.

EvaluateMedTech
How we can help you
EvaluateMedTech

Get commercial intelligence on predicted global performance to 2024 and beyond with consensus forecasts and integrated analysis for the medical device and diagnostic industry.

custom solutions
OUR SERVICES
Custom Solutions

Improve your strategic decision-making with customised solutions that draw on our team of industry experts and trusted commercial intelligence. 

How Evaluate can help you

From market sizing to asset screening

Our connected, calibrated industry data is used by clients around the world to support strategy development, major investment decisions and business planning.

How we can help you
Evaluate services
Vantage news articles
Vantage logo

Daily analysis of key industry developments, underpinned by Evaluate’s industry data. We don’t just tell you what’s happened – we tell you what it means for you.

Signup for Vantage

Evaluate is not a package I can do without... It's an absolute timesaver, and if you're saving time you're saving money.

ANTHONY M, SENIOR DIRECTOR, COMPETITIVE INTELLIGENCE & PROSPECTION, NOVARTIS

Evaluate makes it possible for us to assess the commercial value for different products, as well as understand the major trends in the pharmaceutical industry.

DR. HIROHISA NAKADA, ASSOCIATE DIRECTOR, BUSINESS DEVELOPMENT, OTSUKA HOLDINGS